CIENCIASMEDICASNEWS

miércoles, 23 de septiembre de 2026

FDA Accepts Wearable Sensor-Derived Foot Drop Metrics Under ISTAND as Longitudinal Outcome Measures in Rare Neurological Condition

https://www.fda.gov/drugs/drug-alerts-and-statements/fda-accepts-wearable-sensor-derived-foot-drop-metrics-under-istand-longitudinal-outcome-measures?utm_medium=email&utm_source=govdelivery FDA Accepts Wearable Sensor-Derived Foot Drop Metrics Under ISTAND as Longitudinal Outcome Measures in Rare Neurological Condition The Food and Drug Administration's Innovative Science and Technology Approaches for New Drugs (ISTAND) program has accepted a letter of intent (LOI) for a wearable sensor-derived digital outcome measure intended to quantify foot drop severity and its impact on gait in adult patients with Charcot-Marie-Tooth disease type 1A (CMT1A), a progressive, degenerative disease. This LOI represents the first submission to be accepted into the ISTAND program for a digital health technology (DHT) for a rare neurological condition. This LOI represents both a DHT and a novel approach to outcome measurement in neuromuscular drug development, both important areas of focus for CDER. Launched in 2020, the ISTAND program aims to support the development of novel DDTs for use in regulatory applications for new medical products, particularly tools that do not readily fit into established qualification pathways, such as those for biomarkers and clinical outcome assessments. The program opens opportunities for DDTs that address specific drug development needs and demonstrate feasibility and scientific merit. The LOI acceptance is based on several factors, including the scientific merit of the submission, the ability of the DDT to address a specified drug development need, the availability of supporting information and resources, and the feasibility and practicality of implementation.

Limiting Sugar Before Age 2 Reduces Risk of Dementia, Anxiety: Study Experts say the first 1,000 days after conception is a critical window for brain health By Vanessa Etienne

Limiting Sugar Before Age 2 Reduces Risk of Dementia, Anxiety: Study Experts say the first 1,000 days after conception is a critical window for brain health By Vanessa Etienne https://people.com/limiting-sugar-before-age-2-reduces-risk-of-dementia-anxiety-study-12030940?utm_source=Live+Audience&utm_campaign=19641a4507-nature-briefing-daily-20260922&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Sugar-rationed babies saw host of benefits A study of people who lived their early life during post-war sugar rationing in the United Kingdom found that they had lower risks of all-cause dementia, Alzheimer’s disease, depression and anxiety than people born after rationing ended. A separate study found they were much less likely to develop certain cancers later in life. Even in adulthood, low-sugar babies continued to consume less sugar and had healthier diets overall. “This suggests that the level of sweetness people are exposed to very early in life may shape their taste preferences for a long time,” says economist Weilong Zhang, who co-authored the latter study. https://theconversation.com/babies-born-under-sugar-rationing-grew-into-adults-with-lower-cancer-risk-289873?utm_source=Live+Audience&utm_campaign=19641a4507-nature-briefing-daily-20260922&utm_medium=email&utm_term=0_-33f35e09ea-50432164

‘Epigenetic’ editing is here: gene-tagging technique banishes hepatitis B virus The technique uses chemical tags to shut down viral DNA lurking in a host’s genome. By Miryam Naddaf

https://www.nature.com/articles/d41586-026-02981-9?utm_source=Live+Audience&utm_campaign=19641a4507-nature-briefing-daily-20260922&utm_medium=email&utm_term=0_-33f35e09ea-50432164 Epigenetic editing could treat hep B A treatment that adds chemical tags to the genome of the hepatitis B virus (HBV) can shut down the virus’s gene activity and prevent it from producing viral particles. The therapy, which achieved promising results in experiments on human liver cells and in mice, could be used to treat chronic hepatitis B, a lingering liver infection that affects more than 250 million people worldwide. A clinical trial to test the treatment in people is already under way, with the first participant receiving an intravenous infusion in January this year.

Advancing Lymphoma Care With CAR T-Cell Therapies CME Thursday, 15 October 2026 | 12:00 PM - 12:45 PM ET | 18:00 - 18:45 CEST Virtual

https://na.eventscloud.com/website/98976/ Join our live, 45-minute webinar, "Advancing Lymphoma Care With CAR T-Cell Therapies," designed for hematology/oncology physicians, nurses, and pharmacists in the United States and Europe. Led by global experts, this session helps you safely integrate chimeric antigen receptor (CAR) T-cell therapies into your practice for B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). You will learn to navigate regional approvals and clinical data, streamline patient referrals and care handoffs, and manage toxicities like cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). The webinar ends with a 15-minute live Q&A where you can ask the experts your questions directly. Register now to help improve care and access for your patients. You will learn to navigate regional approvals and clinical data, streamline patient referrals and care handoffs, and manage toxicities like cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS). The webinar ends with a 15-minute live Q&A where you can ask the experts your questions directly. Register now to help improve care and access for your patients.